DMAA
Drugs Made In America Acquisition Corp. (NASDAQ)
Financial Services — Shell Companies
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
None
$10.64
$-0.01 (-0.09%)
Sign in to add DMAA to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $258.31M |
| P/E Ratio (TTM) | 53.20 |
| Forward P/E | - |
| EPS (TTM) | $0.20 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 73.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.65 |
| 52-Week Low | $10.17 |
| 50-Day Avg | $10.60 |
| 200-Day Avg | $10.44 |
| Avg Volume | 116.6K |
| Volume | 100.1K |
Performance Analysis
BEARISHDMAA is flashing more cautionary signals — investors should monitor closely.
-
Trading near its 52-week high ($10.65), which may indicate limited upside.
-
RSI at 73.3 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
-
P/E of 53.2 is elevated — the market expects high growth or it may be overvalued.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:06 UTC
Back to Screener Export Report